Neurocrine Reports Data From KINECT-HD Study Evaluating INGREZZA in Huntington’s Disease (HD)

• Neurocrine reported new post-hoc patient data from the P-III KINECT-HD study (n=128; 18-75yrs.) showing significant reductions in cognitive and motor-related burden with INGREZZA (valbenazine) vs. PBO in HD chorea
• At maintenance (10-12wks.), INGREZZA showed greater mean score reductions across 18 cognition items and 32 of 33 motor items vs PBO. The study used the UHDRS TMC score as the 1EP, and the 2EPs include CGI-C and PGI-C assessments of overall change from baseline
• The data from KINECT-HD will be presented at the 2025 ATMRD Congress, demonstrating cognitive and motor burden reduction using a VMAT2 inhibitor in HD chorea

Ref: Prnewswire| Image: Neurocrine| Press Release

Related News:- Neurocrine’s Crenessity (Crinecerfont) Secures the US FDA’s Approval to Treat Adults and Pediatrics with Congenital Adrenal Hyperplasia (CAH)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com